Sanofi (SNY) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Takeda Pharmaceutical (TAK) has outperformed Sanofi (SNY) over the past year, gaining 33.0% versus a loss of 17.6%. Over five years, TAK leads with a +32.8% price change compared with -17.6% for SNY. Sanofi is the larger company by market cap ($96.01 billion vs $59.83 billion), about 1.6 times the size.
On valuation, Sanofi trades at a lower forward P/E (7.4x vs 35.3x for Takeda Pharmaceutical). Takeda Pharmaceutical offers the higher dividend yield (1067.81% vs 10.28%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNY | TAK |
|---|---|---|
| Share price | $40.07 | $18.73 |
| Market cap | $96.01B | $59.83B |
| 1-day change | -0.40% | +1.13% |
| YTD return | -16.98% | +20.14% |
| 1-year return | -17.56% | +33.03% |
| 5-year return | -17.65% | +32.84% |
| P/E ratio (TTM) | 21.20 | — |
| Forward P/E | 7.42 | 35.34 |
| EPS (TTM) | $1.89 | $-0.34 |
| Dividend yield | 10.28% | 1067.81% |
| Annual dividend | $4.12 | $200.00 |
| 52-week high | $52.68 | $19.10 |
| 52-week low | $39.18 | $12.99 |
| Distance from 52-week high | -23.94% | -1.94% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +33.79% | +17.25% |
| Average volume | 2.87M | 3.06M |
| Shares outstanding | 2.40B | 3.19B |
| Employees | 74,846 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TAK has outperformed SNY by 50.6 percentage points over the past year.
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1067.81% vs 10.28%).
About Sanofi
SNY stock →Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
SNY vs TAK FAQ
Which is bigger, Sanofi or Takeda Pharmaceutical?
Sanofi (SNY) is larger, with a market capitalization of $96.01B compared with $59.83B for Takeda Pharmaceutical (TAK).
Which stock has performed better over the past year, SNY or TAK?
TAK returned +33.03% over the past 12 months, compared with -17.56% for SNY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Sanofi or Takeda Pharmaceutical?
Takeda Pharmaceutical has the higher yield at 1067.81%, compared with 10.28% for Sanofi.
Are Sanofi and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.